IBD Biological Treatment: How the Drug Classes Differ
6 min · Written by a Crohn's patient on biologic therapy
IBD biological treatment means using an antibody based drug to block one specific part of the immune response that drives inflammation in Crohn's disease or ulcerative colitis. There are four families in routine use: anti-TNF drugs, an anti-integrin drug, anti-IL-12/23 drugs, and the newer anti-IL-23 drugs. They are given by drip or by injection, they take weeks rather than days to work, and which one you start on depends far more on your disease pattern than on any ranking of best to worst.
This article is written for informational purposes and reflects personal patient experience. It does not replace medical advice. Always consult your gastroenterologist before changing your treatment.
What separates a biologic from the older drugs
Steroids and immunosuppressants like azathioprine work broadly. They dial down large parts of the immune system and you feel that in the side effects. A biologic is targeted: it is a manufactured antibody that binds one molecule or one receptor and blocks it, leaving the rest of the immune response more or less alone.
Two consequences follow from that, and both matter in daily life. The first is that biologics are proteins, so they cannot survive the stomach. They have to be infused or injected, never swallowed. The second is that your immune system can learn to recognise them as foreign and produce antibodies against them, which is the mechanism behind most cases of a drug quietly stopping work after a year or two.
Worth naming here: JAK inhibitors such as upadacitinib and tofacitinib, and S1P modulators such as ozanimod, are tablets and are not biologics, even though they are often discussed in the same appointment. They are grouped as advanced therapies alongside biologics because they occupy the same place in treatment decisions.
The four classes, side by side
This is the part of IBD biological treatment that is genuinely useful to understand, because the class explains most of what you will experience.
| Class | Drugs | How it is given | Typical situation |
|---|---|---|---|
| Anti-TNF | Infliximab, adalimumab, certolizumab, golimumab | IV every 8 weeks, or self-injection every 1 to 2 weeks | Severe disease, fistulas, joint or skin involvement |
| Anti-integrin | Vedolizumab | IV every 8 weeks, or self-injection after loading | When infection risk is a concern, or after anti-TNF failure |
| Anti-IL-12/23 | Ustekinumab | One weight based IV dose, then self-injection every 8 to 12 weeks | Crohn's after anti-TNF failure, and increasingly first line |
| Anti-IL-23 | Risankizumab, mirikizumab, guselkumab | IV loading, then self-injection | Newer option, both Crohn's and ulcerative colitis |
Anti-TNF drugs act fastest and are the ones reached for when someone is admitted with severe disease. Vedolizumab acts almost only in the gut, which is why it carries a lower systemic infection risk and also why it does nothing for the joint pain some people hope it will fix. The IL-23 blockers are the most recent arrivals and their appeal is a side effect profile that so far looks quiet.
How your first biologic actually gets chosen
Patients often assume there is a ranked list. In practice the decision runs through a handful of questions:
- Crohn's or ulcerative colitis, and where in the bowel. Not every drug is licensed for both.
- Are there fistulas or perianal disease. This pushes strongly towards anti-TNF.
- Is there anything outside the gut, such as arthritis, uveitis or skin involvement. Anti-TNF and IL blockers treat those, vedolizumab does not.
- How urgent is it. Someone in hospital on steroids needs a drug that works in days.
- Infection history, age, and previous cancer. These push towards the gut selective options.
- What your health system or insurer will fund first, which in many countries still shapes the order more than anyone would like.
The mechanics of what happens once a drug is chosen, from loading doses to what infusion day looks like, are covered in our guide to biologic treatment for Crohn's disease.
Infusion or injection
Several of these drugs now exist in both forms, so two people on the same molecule can have completely different routines. An infusion means travel, a waiting room, and bloods before every dose. An injection means a pen in your fridge and a reminder on your phone.
The trade is not just convenience. Infusion appointments come with automatic contact: someone checks your bloods, someone notices if you look unwell, and a missed dose is visible to the unit. When people switch to home injections, that scaffolding disappears and has to be replaced by something you do yourself. The people who do well after switching are the ones who kept logging.
How long before you know it is working
The honest answer is longer than anyone wants. Anti-TNF drugs can produce a noticeable change within one to two weeks in severe disease, but the formal assessment point is usually week 12 to 14, after the loading doses are complete. Ustekinumab and the IL-23 blockers sit in a similar range. Vedolizumab is the slow one and may need up to 6 months before it is fair to call it a failure.
Feeling better is not the same as the inflammation settling. Calprotectin and CRP are checked because symptoms and healing can move apart in both directions, and treatment decisions are made on the numbers and the scope, not on how you describe the last fortnight. The Crohn's & Colitis Foundation keeps a plain summary of what each approved biologic targets and how it is delivered.
When a biologic stops working
Roughly a third of people lose response to their first biologic within a year, and that is expected rather than a sign anything went wrong. What matters is what happens next, because the reason changes the fix.
Low drug level, no antibodies
The drug is being cleared too fast or the interval is too long. The answer is usually a higher dose or a shorter gap between doses, not a new drug. This is the outcome you want, because it keeps a working drug in play.
Low drug level, high antibodies
Your immune system is neutralising the drug. Adding an immunosuppressant sometimes rescues it, but more often this means switching. Whether you move within the class or to a different one depends on the antibody level.
Normal drug level, still symptomatic
The target itself is not driving your inflammation, or the symptoms are coming from something else such as bile salt malabsorption, a stricture, or bacterial overgrowth. Switching to another anti-TNF here is unlikely to help. This is when the class changes. Therapeutic drug monitoring in IBD is well documented in the literature and is the reason these three situations are separated before anyone reaches for a new prescription.
Safety and what gets monitored
Starting IBD biological treatment involves screening for tuberculosis and hepatitis B, a check of your vaccination record, and a discussion about live vaccines, which are off the table while you are on treatment. After that, blood tests every 8 to 12 weeks are standard.
The risk that matters day to day is infection, and it is modest rather than dramatic: a higher chance of chest and skin infections, and a longer recovery from ordinary illnesses. Anti-TNF drugs carry the most of this, vedolizumab the least. Against that sits the risk of leaving inflammation untreated, which includes surgery, strictures and bowel cancer, and which is why most gastroenterologists push towards treating rather than waiting. Our article on biologics side effects and flares on treatment goes into separating a drug effect from disease activity, which is harder than it sounds.
If you travel, biologics add paperwork: a letter for airport security, a cool bag for pens, and in some countries an arrangement to receive an infusion abroad. IBD Passport maintains country by country guidance on this.
What to track so the next decision is easier
Every decision to change IBD biological treatment is made on evidence you supply. Four things carry weight:
- End of cycle symptoms. The exact days symptoms return before your next dose. A pattern starting at week 6 of an 8 week cycle is what triggers a drug level check.
- Post dose days. Fatigue, headache or aching joints in the 48 hours after a dose, so a drug effect is not mistaken for a flare.
- Infections and antibiotics. The real count, not an estimate. This directly shapes which class is considered next.
- Delays and missed doses, with the reason, since gaps drive antibody formation.
Turning up and saying the last few months have been rough leads nowhere. Turning up with the specific weeks, and the pattern inside them, is what moves an appointment from reassurance to a decision. If symptoms are currently building, the step by step approach in our flare management plan is the more immediate read.
Frequently asked questions
What is the best biological treatment for IBD?
There is no single best drug. The choice turns on whether you have Crohn's or ulcerative colitis, whether there are fistulas or joint involvement, how urgent things are, and what you have already tried. Anti-TNF drugs lead in severe and fistulising Crohn's; vedolizumab is often chosen when infection risk is the bigger worry.
How long does it take for an IBD biologic to work?
Assessment usually happens at week 12 to 14, after loading. Anti-TNF drugs can act within days in severe disease. Vedolizumab is slower and may need up to 6 months before it is judged a failure.
What happens if my biologic stops working?
Drug levels and antibodies get checked first. A low level with no antibodies usually means adjusting dose or interval. A low level with high antibodies usually means switching drug, and often switching class.
Are IBD biologics safe long term?
Anti-TNF registry data now covers more than twenty years. Infection is the main risk, which is why vaccination status and regular bloods matter. Untreated inflammation carries the larger risk for most people, which is the comparison your gastroenterologist is actually making.
Can I stop treatment once I am in remission?
Sometimes, but relapse after stopping runs around 30 to 50 percent within two years, and restarting the same drug does not always work as well. The decision rests on healing seen on scope and on calprotectin, not on feeling well.
Is a biosimilar the same as the original?
For practical purposes, yes. Same schedule, same monitoring, same expected effect, and switching studies in IBD have not shown a loss of response. Keep logging through a switch so any real change shows up in your own records rather than being assumed.
Before your next appointment, write down which weeks of your current cycle were worst and how many courses of antibiotics you have had this year. Those two lines are what a drug level check or a class switch usually gets decided on.
